Financials
Financial year 2024
Gross margin
€ 2 million
▼ 27% vs 2023
Profit
Healthy€ 531,056
▼ 59% vs 2023
Debts
Low€ 2.4 million
▲ 20% vs 2023
Anima Research from Alken, company number BE0452135608, closed financial year 2024 with a result of € 531,056 after tax. For that financial year Anima Research recorded a gross margin of € 2 million and equity of € 4.8 million. Compared with financial year 2023, the result moved from € 1.3 million to € 531,056. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 4, 2025.
What happened at Anima Research?
What happened at Anima Research in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 531,056 (▼ 59% vs 2023). Source: NBB ↗
- EB PHARMA DEVELOPMENTS BV became a director. NBB
- BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM NV became a director. NBB
- BAMBRIDGE BV became a director. NBB
- MAREN BUNTINX became a director. NBB
- ERIK BUNTINX stepped down as director. NBB
- ERIK BUNTINX became a director. NBB
- New establishment in Diepenbeek. KBO
In short
From € 1.3 million profit in 2021 to € 531,056 profit in 2024.
Paid € 1.5 million in corporate taxes since 2021.
Best year ever: 2023, with € 1.3 million profit.
On average € 279,900 of value added per employee in 2024.
A new publication or filing at Anima Research? We notify you, reason included.
Follow Anima ResearchNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Anima Research are EB PHARMA DEVELOPMENTS BV, BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM NV, BAMBRIDGE BV and MAREN BUNTINX. The same people are also behind ANEUROTECH, HET ANKER, STUDIO 100, PLOPSA and THEODORUS III.
Directors
According to the 2024 annual accounts
since 2024
BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM NV
Director · represented by VERMEULEN SVEN
Also active at: HET ANKER, STUDIO 100, PLOPSA +4 more
since 2024
Director · represented by DE CLIPPEL ERIK
Also active at: DEGROOF PETERCAM CORPORATE FINANCE
since 2024
since 2024
ERIK BUNTINX
Director
Also active at: B & B BEHEER, INTEGRA INVEST Alken, EB Pharma Developments +3 more
since 2021 · until 2024
Establishments
Establishment units
Physical locations of this company
Alkerstraat 28
3570 Alken
Wetenschapspark 11-13
3590 Diepenbeek
Active since 1 April 2021
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
Details
- Company number
- 0452.135.608
- VAT number
- BE 0452.135.608
- Registered office
- Alkerstraat 28, 3570 Alken
- Names & denominations
- Anima Research
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 February 1994
- Peppol
- Active · Active since 1 Dec 2025
- Contact
- 011/31.62.72
- Activities · NACE
Activiteiten van medisch specialisten
Medische praktijken
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige technische testen en toetsen